SYMPLIFY, a prospective observational study, is the first large-scale evaluation of a multi-cancer early detection (MCED) test in individuals who presented with symptoms to primar ...

“With newer advances, cancer care has definitely reached a point where it is no longer a threat to life, but a journey that ...

BERLIN -- Adding a test that predicts cancer signal origin to single standard of care (SoC) screening substantially increased ...

Blood test to aid cancer treatment and recurrence monitoring now available from a German lab for potentially faster results ...

A cancer diagnosis can be overwhelming, but today there is more reason for hope than ever before – survival and recovery are increasingly possible. At the heart of this progress is technology that not ...

Biomarkers are pivotal for confirming diagnoses, predicting disease progression, and tailoring therapeutic modalities. Recent ...

Priya Hays discusses the integration of AI into personalized medicine (PM), highlighting its potential to enhance healthcare ...

Recent headlines proclaim a ‘potential’ or ‘functional’ cure for multiple myeloma, but the fight against the disease must ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

More Than Half of Cancers Detected by Galleri Were Early Stage Approximately Three-Quarters of Galleri-Detected Cancers Do Not Have Recommended Screenings ...

Interestingly, while only 16% of oncology researchers reported using AI in biomarker detection and assessment at the time of ...